Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Bufalin
80
CHF
CHF 80.00
In stock
AG-CN2-0533-M01010 mgCHF 80.00
AG-CN2-0533-M05050 mgCHF 320.00
| Product Details | |
|---|---|
| Synonyms | (3β,5β)-3,14-Dihydroxy-bufa-20,22-dienolide; NSC 89595; BRN 5141601 |
| Product Type | Chemical |
| Properties | |
| Formula |
C24H34O4 |
| MW | 386.5 |
| CAS | 465-21-4 |
| RTECS | EI2962500 |
| Source/Host Chemicals | Isolated from venenum bufonis. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO (5mg/ml), ethanol (15mg/ml) or DMF (20mg/ml). |
| Identity | Determined by 1H-NMR. |
| InChi Key | QEEBRPGZBVVINN-BMPKRDENSA-N |
| Smiles | C[C@@]12[C@@](CC[C@@H]2C3=COC(C=C3)=O)(O)[C@]4([H])CC[C@]5([H])C [C@@H](O)CC[C@]5(C)[C@@]4([H])CC1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Protect from light. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Bufalin is a cardiotonic steroid with anaesthetic, blood pressure stimulatory and respiratory activities.
- It is a potent Na+/K+-ATPase transporter inhibitor (Kd = 42, 45, and 40nM for the α1, α2, and α3 subunits, respectively).
- Bufalin has anticancer effects in a variety of cancer cell lines both in vitro and in vivo. It inhibits cancer cell proliferation, induces cell cycle arrest, induces apoptosis and autophagy, inhibits angiogenesis and neovascularization, induces cell differentiation, inhibits cancer metastasis and invasion, and enhances chemotherapeutic drug sensitivity through multiple kinase targets and also the Na+/K+-ATPase transporter. It also inhibits proteins of the steroid receptor coactivator family, such as SRC-1 and SRC-3 at 5nM.
- Bufalin has anti-inflammatory effects by modulating nuclear factor-κB (NF-κB) signaling and down-regulating inflammatory-related genes such as cyclooxygenases, lipoxygenases, inducible nitric oxide synthase (iNOS), and thereby decrease nitric oxide and prostaglandin E2 (PGE2) production.
Product References
- Effects of bufalin and related cardiotonic steroids in the neuromuscular junction: S. Yoshida & T. Sakai; Jpn. J. Pharmacol. 23, 859 (1973)
- Bufalin as a potent inducer of differentiation of human myeloid leukemia cells: L.S: Zhang, et al.; BBRC 178, 686 (1991)
- Chronic blood pressure effects of bufalin, a sodium-potassium ATPase inhibitor, in rats: M.B. Pamnani, et al.; Hypertension 23, I106 (1994)
- Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs: S. Hashimoto, et al.; Leuk. Res. 21, 875 (1997)
- Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase: A. Katz, et al.; J. Biol. Chem. 285, 19582 (2010)
- Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation: C.M. Xie, et al.; Free Radic. Biol. Med. 51, 1365 (2011)
- Bufalin induces lung cancer cell apoptosis via the inhibition of PI3K/Akt pathway: Z. Zhu, et al.; Int. J. Mol. Sci. 13, 2025 (2012)
- Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: new hope for cancer patients: P.H. Yin, et al.; Asian Pac. J. Cancer Prev. 13, 5339 (2012) (Review)
- Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1: Y. Wang, et al.; Cancer Res. 74, 1506 (2014)
- Anti-inflammatory and antinociceptive activities of bufalin in rodents: L. Wen, et al.; Mediators Inflamm. 2014, 171839 (2014)
- Bufalin Inhibits the Inflammatory Effects in Asthmatic Mice through the Suppression of Nuclear Factor-Kappa B Activity: Z. Zhakeer, et al.; Pharmacol. 99, 179 (2017)
- Bufalin sensitizes human bladder carcinoma cells to TRAIL-mediated apoptosis: K.H. Kang, et al.; Oncol. Lett. 14, 853 (2017)
- Cardiac glycoside bufalin blocks cancer cell growth by inhibition of Aurora A and Aurora B activation via PI3K-Akt pathway: C.M. Xie, et al.; Oncotarget 9, 13783 (2018)
- Molecular mechanisms underlying the antimetastatic activity of bufalin: J. Wang, et al.; Mol. Clin. Oncol. 8, 631 (2018) (Review)
- A research update on the anticancer effects of bufalin and its derivatives: Y.L. Lan, et al.; Oncol. Lett. 17, 3635 (2019) (Review)
- New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin: C.S. Cheng, et al.; Cancer Cell Int. 19, 92 (2019) (Review)
Related Products
